The purpose of this study is to evaluate the overall performance of investigational contact lenses (DD T2) when compared to clariti® 1 day contact lenses.

Inclusion Criteria:

• Understand and sign an Informed Consent Form;
• Successful wear of daily disposable spherical soft contact lenses in both eyes for a minimum of 5 days per week and 8 hours per day during the past 3 months;
• Best-corrected visual acuity (BCVA) 20/25 or better in each eye;
• Willing to stop wearing habitual contact lenses for the duration of study participation;
• Other protocol-specified inclusion criteria may apply.

Exclusion Criteria:

• Anterior segment infection, inflammation, or abnormality or disease that contraindicates contact lens wear, as determined by the Investigator;
• Use of systemic or ocular medications for which contact lens wear could be contraindicated, as determined by the Investigator;
• Refractive, ocular, or intraocular surgery, as specified in the protocol;
• Eye condition or injury, as specified in the protocol;
• Current or history of intolerance, hypersensitivity, or allergy to any component of the study products;
• Wearing habitual contact lenses in an extended wear modality (routinely sleeping in lenses for at least 1 night per week) over the last 3 months prior to enrollment;
• Use of topical ocular medications and artificial tear or rewetting drops requiring instillation during contact lens wear;
• Currently wearing clariti® 1 day contact lenses;
• Habitually wearing monovision or multifocal lenses during the last 3 months;
• Other protocol-specified exclusion criteria may apply.

This analysis population includes all subjects/eyes exposed to any study lenses evaluated in this study (Safety Analysis Set).

Dispense through study completion, approximately 20 days

An adverse event (AE) was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs in subjects, users or other persons, whether or not related to the investigational medical device. AEs were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. Safety Analysis Set, based on treatment-specific exposure.